AC
CRSP icon

Amia Capital’s CRISPR Therapeutics CRSP Stock Holding History

Amia Capital’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-4,374
Closed -$366K – 12
2020
Q3 		$366K Buy
4,374
+272
+7% +$24.1K 0.43% 25
2020
Q2 		$301K Sell
4,102
-2,263
-36% -$132K 0.25% 27
2020
Q1 		$270K Sell
6,365
-2,062
-24% -$106K 0.24% 30
2019
Q4 		$513K Buy
+8,427
New +$460K 0.15% 32

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
VVM
Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
WRF
Waddell & Reed Financial Overland Park, Kansas $48.6B AUM 84.78% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Amia Capital's CRSP Position: Q4 2020 in Review

Amia Capital sold out of CRISPR Therapeutics (CRSP) in Q4 2020, closing a stake of 4,374 shares — an estimated $366K sold.

Amia Capital first reported a position in CRSP in Q4 2019 and held it in 4 quarters. The position peaked at $513K in Q4 2019. 412 funds tracked by Wall St. Rank hold CRSP as of Q4 2020.

  • Amia Capital reported no remaining CRISPR Therapeutics position as of Q4 2020 after selling out during the quarter.
  • Amia Capital sold 4,374 CRISPR Therapeutics shares in Q4 2020, an estimated $366K.
  • Amia Capital first reported a position in CRISPR Therapeutics in Q4 2019 and held it in 4 quarters.
  • Amia Capital's CRISPR Therapeutics position peaked at $513K in Q4 2019.
  • 412 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q4 2020.

Based on Amia Capital's 13F filing for Q4 2020, filed 11 Feb 2021.